Long-term safety and efficacy of cyclosporin a therapy for T-cell large granular lymphocyte leukemia

Leukemia and Lymphoma

Volumn 51, Issue 2, 2010, Pages 338-341

  Pawarode, Attaphol ^a,b   Wallace, Paul K ^a   Ford, Laurie A ^a   Barcos, Maurice ^a   Baer, Maria R ^a,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIHYPERTENSIVE AGENT; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ERYTHROPOIETIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MAGNESIUM; METHOTREXATE; PENTOSTATIN; THYMOCYTE ANTIBODY;

ADULT; AGED; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; KIDNEY FAILURE; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LETTER; LEUKEMIA REMISSION; LONG TERM CARE; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; T CELL LEUKEMIA;

AGED; AGED, 80 AND OVER; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 76349094088     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903470851     Document Type: Letter

References (14)

1. Chan WC, Foucar K, Morice WG, Catovsky D. T-cell large granular lymphocyte leukaemia. In: Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. pp 272-273.
2. Yang J, Epling-Burnette PK, Painter JS, et al. Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood 2008;111:1610-1616.
3. Zhang R, Shah MV, Yang J, et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci USA 2008;105:16308-16313.
4. Schade AE, Wlodarski MW, Maciejewski JP. Pathophysiology defined by altered signal transduction pathways: the role of JAK-STAT and PI3K signaling in leukemic large granular lymphocytes. Cell Cycle 2006;5:2571-2574.
5. Schade AE, Powers JJ, Wlodarski MW, Maciejewski JP. Phosphatidylinositol- 3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. Blood 2006;107:4834-4840.
6. Shah MV, Zhang R, Irby R, et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 2008;112:770-781.
7. Osuji N, Matutes E, Tjonnfjord G, et al. T-cell large granular lymphocyte leukemia: a report on the treatment of 29 patients and a review of the literature. Cancer 2006; 107:570-578.
8. Aribi A, Huh Y, Keating M, et al. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. Leuk Res 2007;31:939-945.
9. Agnarsson BA, Loughran TP Jr., Starkebaum G, Kadin ME. The pathology of large granular lymphocyte leukemia. Hum Pathol 1989;20:643-651.
10. Sood R, Stewart CC, Aplan PD, et al. Neutropenia associated with T-cell large granular lymphocyte leukemia: long-term response to cyclosporine therapy despite persistence of abnormal cells. Blood 1998;91:3372-3378.
11. Loughran TP Jr, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 1994;84:2164-2170.
12. FujishimaN,SawadaK,HirokawaM, et al.Long-termresponses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 2008;93:1555-1559.
13. Sokol L, Loughran TP Jr. Large granular lymphocyte leukemia. Oncologist 2006;11:263-273.
14. Battiwalla M, Melenhorst J, Saunthararajah Y, et al. HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders. Br J Haematol 2003;123:449-453.